Orphan Technologies Ltd.

Travere Therapeutics, Inc. thinks it is ready to move its second pipeline asset into a pivotal Phase III program, after reporting data from a Phase I/II study of pegtibatinase (TVT-058) that showed r

Retrophin, Inc. is turning to business development to build its rare disease-focused pipeline about a year after a Phase III failure threw its plans into disarray – the biotech has agreed to pay $90m

IN VITRO DIAGNOSTICS Carmenta Bioscience Inc. Stanford University Carmenta Bioscience gets option to IP from Stanford University Stanford University has granted 2012 university spin-off Carmen